Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

Leukemia

Volumn 23, Issue 5, 2009, Pages 994-997

  Vandyke, K ^a,b   Dewar, A L ^a   Farrugia, A N ^a   Fitter, S ^a   Bik To, L ^a   Hughes, T P ^a   Zannettino, A C W ^a,b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; DASATINIB; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE REMODELING; CANCER CELL CULTURE; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 67349149693     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.356     Document Type: Article

References (13)

1. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
2. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 2006; 103: 3153-3158.
3. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2309.
4. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127-3132.
5. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006; 107: 4334-4337.
6. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002; 99: 111-120.
7. Wang X, Hochhaus A, Kantarjian HM, Agrawal S, Roy A, Pfister M et al Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol 2008; 26 (Suppl): 3590.
8. Xing L, Venegas AM, Chen A, Garrett-Beal L, Boyce BF, Varmus HE et al Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 2001; 15: 241-253.
9. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 1993; 90: 4485-4489.
10. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992; 90: 1622-1627.
11. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM et al Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111: 2538-2547.
12. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006-2013.
13. Grey A, O'Sullivan S, Reid IR, Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006; 355: 2494-2495.